Value of direct-acting antivirals combined with PR regimen (PEG-IFN combined with ribavirin) in the new era of antiviral therapy for hepatitis C

• Main Authors: CHEN Xinyue, LIU Yali, REN Shan
• Format: Article
• Language: zho
• Published: Editorial Department of Journal of Clinical Hepatology 2017-06-01
• Series: Linchuang Gandanbing Zazhi
• Online Access: http://www.lcgdbzz.org/qk_content.asp?id=8255

Pegylated interferon (PEG-IFN) combined with ribavirin (PR regimen) has been used in China for more than 10 years. With the development of direct-acting antiviral agents (DAAs), the therapeutic regimens for hepatitis C has become more and more diverse. In the regimen of DAAs combined with PR regimen, IFN helps to benefit the long-term prognosis of patients with chronic hepatitis C (CHC), and the addition of DAAs may improve therapeutic effect, shorten the course of treatment, and further improve the current status of treatment of CHC. This article introduces the advantages and disadvantages of PR regimen, DAAs combined with PR regimen, and oral regimen with DAAs, in order to investigate the therapeutic regimens suitable for different CHC patients and provide a reference for clinical practice.